AstraZeneca

Respiratory syncytial virus (RSV) market report by DelveInsight covers epidemiology, market forecast, and key companies like Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies include Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others.

Sarepta Therapeutics, known for its focus on Duchenne muscular dystrophy, made a $500 million upfront deal with Arrowhead Pharmaceuticals, investing $325 million and up to $10 billion in milestones. The deal aims to diversify Sarepta's pipeline with RNA drugs and expand its portfolio into new disease areas. Despite Elevidys failing a confirmatory trial, Sarepta secured full FDA approval and a label expansion, generating $181 million in Q3. The deal reflects Sarepta's ability to secure regulatory success and diversify its portfolio, potentially offering new options for patients with rare diseases.

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

Lung diseases like asthma, COPD, and lung cancer profoundly impact millions, with interconnected conditions exacerbating symptoms and outcomes. AstraZeneca is committed to addressing these challenges through innovative science, early detection, and equitable access to care, aiming to transform lung health globally.

T.C. has consulted/advised/spoken for ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, Genentech, IDEOlogy Health, Medical Educator Consortium, Medscape, Merck, OncLive, oNKo-innate, PEAK Medicals, PeerView, Pfizer, Physicians’ Education Resource, RAPT Therapeutics, Regeneron, Targeted Oncology. W.N.W.Jr. has consulted/advised/spoken for Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Genentech/Roche, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi-Aventis, Takeda, United Medical.

The global Brain Tumor Diagnosis and Treatment market, valued at $1.5B in 2023, is projected to reach $2B by 2030, growing at a CAGR of 4.3%. Primary and Secondary segments are expected to reach $1.3B and grow at 4.1% and 4.8% CAGR, respectively. Key regions include the U.S., China, Japan, Canada, Germany, and Asia-Pacific. Leading companies profiled are AstraZeneca PLC, Carestream Health, Inc., and GE Healthcare.

Alexion, now part of AstraZeneca, faces challenges in commercializing rare disease drugs due to small patient populations and regulatory hurdles. Scott Weintraub emphasizes the importance of early integration of R&D and commercial strategies. Alexion's mission includes patient-centric development, exemplified by drugs like Strensiq and Ultomiris, which aim to reduce injection frequency and improve patient quality of life. With AstraZeneca, Alexion gains access to advanced diagnostics and global markets, enhancing its ability to address rare diseases and contribute to AstraZeneca's ambitious growth goals.

Tonix Pharmaceuticals appoints Bradley Raudabaugh as VP of Marketing and Errol Gould as VP of Medical Affairs to support the launch of TNX-102 SL for fibromyalgia. The NDA for TNX-102 SL was submitted to the FDA in October 2024, with an expected decision in 2025, potentially marking the first new drug for fibromyalgia in over 15 years.

The biotechnology market, valued at USD 1.38 Trillion in 2023, is projected to reach USD 3.90 Trillion by 2031, driven by technological advancements, investment, and demand for sustainable solutions. Segments include type, product, technology, application, and region. Key trends are personalized medicine, CRISPR, sustainability, and telemedicine. Opportunities include increased funding, emerging markets, collaborations, and regulatory advancements. Major players include AstraZeneca, Gilead Sciences, Biogen, and Merck.

At SCOPE Europe, AstraZeneca's Liz Bristow and Jodie Allen emphasized patient-centered clinical trials, advocating for diversity action plans early in trial design. They highlighted the need for cross-functional collaboration and continuous reflection to address structural barriers and meet diversity goals, using a CKD trial as an example of adapting protocols for inclusivity.